

Advances in Experimental Medicine and Biology 700

Helge Großhans *Editor*

Regulation of microRNAs

LANDES
BIOSCIENCE

 Springer

Regulation of microRNAs

ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY

Editorial Board:

NATHAN BACK, *State University of New York at Buffalo*

IRUN R. COHEN, *The Weizmann Institute of Science*

ABEL LAJTHA, *N.S. Kline Institute for Psychiatric Research*

JOHN D. LAMBRIS, *University of Pennsylvania*

RODOLFO PAOLETTI, *University of Milan*

Recent Volumes in this Series

Volume 692

NEUROPEPTIDE SYSTEMS AS TARGETS FOR PARASITE AND PEST CONTROL

Edited by Timothy G. Geary and Aaron G. Maule

Volume 693

POST-TRANSCRIPTIONAL REGULATION BY STAR PROTEINS

Edited by Talila Volk and Karen Artzt

Volume 694

PROTEIN METABOLISM AND HOMEOSTASIS IN AGING

Edited by Nektarios Tavernarakis

Volume 695

THE CELL BIOLOGY OF STEM CELLS

Edited by Eran Meshorer and Kathrin Plath

Volume 696

SOFTWARE TOOLS AND ALGORITHMS FOR BIOLOGICAL SYSTEMS

Edited by Hamid R. Arabnia and Quoc-Nam Tran

Volume 697

HOT TOPICS IN INFECTION AND IMMUNITY IN CHILDREN VII

Edited by Andrew Pollard, Adam Finn, and Nigel Curtis

Volume 698

BIO-FARMS FOR NUTRACEUTICALS: FUNCTIONAL FOOD AND SAFETY CONTROL BY BIOSENSORS

Maria Teresa Giardi, Giuseppina Rea and Bruno Berra

Volume 699

MCR 2009: PROCEEDINGS OF THE 4TH INTERNATIONAL CONFERENCE ON MULTI-COMPONENT REACTIONS AND RELATED CHEMISTRY, EKATERINBURG, RUSSIA

Maxim A. Mironov

Volume 700

REGULATION OF MICRORNAS

Helge Großhans

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

Regulation of microRNAs

Edited by

Helge Großhans

Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

Springer Science+Business Media, LLC

Landes Bioscience

Springer Science+Business Media, LLC
Landes Bioscience

Copyright ©2010 Landes Bioscience and Springer Science+Business Media, LLC

All rights reserved.

No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system; for exclusive use by the Purchaser of the work.

Printed in the USA.

Springer Science+Business Media, LLC, 233 Spring Street, New York, New York 10013, USA
<http://www.springer.com>

Please address all inquiries to the publishers:
Landes Bioscience, 1806 Rio Grande, Austin, Texas 78701, USA
Phone: 512/ 637 6050; FAX: 512/ 637 6079
<http://www.landesbioscience.com>

The chapters in this book are available in the Madame Curie Bioscience Database.
<http://www.landesbioscience.com/curie>

Regulation of microRNAs, edited by Helge Großhans. Landes Bioscience / Springer Science+Business Media, LLC dual imprint / Springer series: Advances in Experimental Medicine and Biology.

ISBN: 978-1-4419-7822-6

While the authors, editors and publisher believe that drug selection and dosage and the specifications and usage of equipment and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they make no warranty, expressed or implied, with respect to material described in this book. In view of the ongoing research, equipment development, changes in governmental regulations and the rapid accumulation of information relating to the biomedical sciences, the reader is urged to carefully review and evaluate the information provided herein.

Library of Congress Cataloging-in-Publication Data

Regulation of microRNAs / edited by Helge Grosshans.

p. ; cm. -- (Advances in experimental medicine and biology ; v. 700)

Includes bibliographical references and index.

ISBN 978-1-4419-7822-6

1. Small interfering RNA. 2. Genetic regulation. I. Grosshans, Helge. II. Series: Advances in experimental medicine and biology ; v. 700. 0065-2598

[DNLM: 1. MicroRNAs--genetics. 2. Gene Expression Regulation--genetics. W1 AD559 v.700 2010 / WY 105]

QP623.5.S63R445 2010

572.8'8--dc22

2010038832

PREFACE

When in 2001 the first draft versions of the human genome revealed that there were no more than 25,000 human genes, much soul searching resulted. How could a complicated human being develop and function with a gene set not much bigger than that of a worm, *Caenorhabditis elegans*?

Although the meaning of ‘gene counts’ is debatable when a single gene can give rise to a multitude of different gene products (and when in fact much of the ‘inter-genic’ genome appears to be transcribed), the apparent conundrum highlighted the importance of gene regulation in making complex organisms. It thus appears particularly appropriate that it was also in 2001 that microRNAs (miRNAs) were finding their way into the limelight. These regulatory RNAs, named for their small size of some 22 nucleotides, had been discovered in 1993 in *C. elegans*, but were initially considered a worm oddity and largely ignored. It was only when small RNA cloning efforts started to reveal hundreds of different miRNAs in a typical animal or plant genome that they were widely noticed. Today, it appears that hardly any cellular or developmental pathway has escaped the control that miRNAs exert by silencing target mRNAs through an antisense mechanism. Accordingly, miRNAs dysregulation contributes to numerous diseases, most notably diverse cancers.

Given this pervasiveness and importance of miRNA-mediated gene regulation, it should come as little surprise that miRNAs themselves are also highly regulated. However, the recent explosion of knowledge on this topic has been remarkable, providing a primary motivation for publication of this book. As miRNAs are transcribed by RNA polymerase II, the enzyme that also generates mRNAs, it was perhaps not unexpected that miRNA transcription would be subject to regulation, and we have willfully omitted this aspect from this monograph. However, what has been unexpected is the extent of post-transcriptional regulation of miRNAs that is illustrated in this book.

In the first chapter, René Ketting provides the background against which all of the regulatory processes occur by revealing the complex biogenesis and function of miRNAs and the related siRNAs. Akiko Hata and Brandi Davis then describe how SMAD proteins, generally known for their function in controlling transcription, reveal another side in regulating the processing of certain primary miRNA (pri-miRNA) transcripts by the RNase Drosha. Drosha-mediated processing of pri-miRNAs into the short precursor

miRNAs (pre-miRNAs) is also modulated by the RNA-binding proteins hnRNP A1, as discussed by Javier Caceres and colleagues and KSRP (Michele Trabucchi et al). Whereas SMADs, hnRNP A1 and KSRP promote processing of specific pri-miRNAs, estrogen receptor alpha represses this biogenesis step as related by Shigeaki Kato and colleagues. Robinson Triboulet and Richard Gregory further reveal that the pri-miRNA processing complex undergoes autoregulation.

KSRP not only promotes processing of pri-miRNAs, but also the subsequent cleavage of pre-miRNAs by the RNase Dicer. Conversely, Lin28 was found to repress pri-miRNA as well pre-miRNA processing as discussed by Nicolas Lehrbach and Eric Miska. This inhibition involves 3' end uridylation of the pre-miRNA. Another RNA modification that occurs on miRNAs is adenosine-to-inosine editing, and Mary O'Connell and colleagues critically evaluate its incidence and how editing affects processing and functionality of miRNAs.

Gregory Wulczyn and colleagues discuss the Trim-NHL protein family whose members utilize diverse mechanisms to regulate miRNA levels and activity both positively and negatively. Nicole Meisner and Witold Filipowicz review HuR, an RNA-binding protein that regulates mRNAs through a number of mechanisms, including at least one instance in which HuR reverses miRNA-mediated mRNA silencing.

Finally, although mature miRNAs have long been viewed as highly stable molecules, miRNA degradation pathways have now been identified in plants and algae, as revealed by Heriberto Cerutti and Fadia Ibrahim, and in animals, as discussed by us.

Even if this monograph cannot strive to be comprehensive in a field developing at such an amazing pace, I hope that the examples provided here will serve to illustrate the diversity of mechanisms regulating miRNAs, as well as highlight some unifying themes, particularly among the mechanisms regulating miRNA biogenesis. Undoubtedly, many more examples of regulation of miRNAs remain to be discovered and mechanistic details on known pathways to be revealed, promising an exciting future to this field of research.

*Helge Großhans, PhD
Friedrich Miescher Institute for Biomedical Research
Basel, Switzerland*

ABOUT THE EDITOR...



HELGE GROBHANS, PhD is a research group leader at the Friedrich Miescher Institute for Biomedical Research (FMI), which is part of the Novartis Research Foundation in Basel, Switzerland. His main research interests are in the developmental function, regulation, and mechanism of action of microRNAs. He received his PhD from the University of Heidelberg, Germany and did his postdoctoral training at Yale University, USA. He is the winner of a 2009 ERC Award.

PARTICIPANTS

Paola Briata
Istituto Nazionale per la Ricerca
sul Cancro (IST)
Genova
Italy

Javier F. Cáceres
Medical Research Council
Human Genetics Unit
Institute of Genetics
and Molecular Medicine
Western General Hospital
Edinburgh
UK

Heriberto Cerutti
School of Biological Sciences
Center for Plant Science Innovation
University of Nebraska
Lincoln, Nebraska
USA

Saibal Chatterjee
Friedrich Miescher Institute
for Biomedical Research
Basel
Switzerland

Elisa Cuevas
Center for Anatomy
Institute of Cell Biology and Neurobiology
Charité-Universitätsmedizin Berlin
Berlin
Germany

Brandi N. Davis
Department of Biochemistry
Tufts University School of Medicine
and
Molecular Cardiology Research Institute
Tufts Medical Center
Boston, Massachusetts
USA

Witold Filipowicz
Friedrich Miescher Institute
for Biomedical Research
Basel
Switzerland

Eleonora Franzoni
Center for Anatomy
Institute of Cell Biology and Neurobiology
Charité-Universitätsmedizin Berlin
Berlin
Germany

Sally Fujiyama-Nakamura
Institute of Molecular and Cellular
Biosciences
University of Tokyo
Tokyo
Japan

Roberto Gherzi
Istituto Nazionale per la Ricerca
sul Cancro (IST)
Genova
Italy

Richard I. Gregory
Stem Cell Program
Children's Hospital Boston
and
Department of Biological Chemistry
and Molecular Pharmacology
Harvard Medical School
Harvard Stem Cell Institute
Boston, Massachusetts
USA

Helge Großhans
Friedrich Miescher Institute
for Biomedical Research
Basel
Switzerland

Sonia Guil
Cancer Epigenetics and Biology Program
(PEBC)
Catalan Institute of Oncology
(ICO-IDIBELL)
L'Hospitalet Barcelona
Catalonia
Spain

Akiko Hata
Department of Biochemistry
Tufts University School of Medicine
and
Molecular Cardiology Research Institute
Tufts Medical Center
Boston, Massachusetts
USA

Bret S.E. Heale
Medial Research Council
Human Genetics Unit
Institute of Genetics and Molecular
Medicine
Western General Hospital
Edinburgh
UK

Fadia Ibrahim
School of Biological Sciences
Center for Plant Science Innovation
University of Nebraska
Lincoln, Nebraska
USA

Shigeaki Kato
Institute of Molecular and Cellular
Biosciences
University of Tokyo
Tokyo
Japan

Liam P. Keegan
Medial Research Council
Human Genetics Unit
Institute of Genetics and Molecular
Medicine
Western General Hospital
Edinburgh
UK

René F. Ketting
Hubrecht Institute-KNAW
University Medical Centre Utrecht
Utrecht
The Netherlands

Nicolas J. Lehrbach
Wellcome Trust Cancer Research
Gurdon Institute and Department
of Biochemistry
University of Cambridge
Cambridge
UK

Nicole-Claudia Meisner
Novartis Institutes for Biomedical Research
Novartis Campus
Basel
Switzerland

Eric A. Miska
Wellcome Trust Cancer Research
Gurdon Institute and Department
of Biochemistry
University of Cambridge
Cambridge
UK

PARTICIPANTS

xi

Gracjan Michlewski
Medical Research Council
Human Genetics Unit
Institute of Genetics and Molecular
Medicine
Western General Hospital
Edinburgh
UK

Mary A. O'Connell
Medial Research Council
Human Genetics Unit
Institute of Genetics and Molecular
Medicine
Western General Hospital
Edinburgh
UK

Andres Ramos
Division of Molecular Structure
National Institute for Medical Research
The Ridgeway, London
UK

Michael G. Rosenfeld
Howard Hughes Medical Institute
Department and School of Medicine
University of California, San Diego
La Jolla, California
USA

Agnieszka Rybak
Max Delbrück Center for Molecular
Medicine
Berlin
Germany

Michele Trabucchi
Howard Hughes Medical Institute
Department and School of Medicine
University of California, San Diego
La Jolla, California
USA

Robinson Triboulet
Stem Cell Program
Children's Hospital Boston
and
Department of Biological Chemistry
and Molecular Pharmacology
Harvard Medical School
Harvard Stem Cell Institute
Boston, Massachusetts
USA

F. Gregory Wulczyn
Center for Anatomy
Institute of Cell Biology and Neurobiology
Charité-Universitätsmedizin Berlin
Berlin
Germany

Kaoru Yamagata
Institute of Molecular and Cellular
Biosciences
University of Tokyo
Tokyo
Japan

CONTENTS

1. microRNA BIOGENESIS AND FUNCTION: AN OVERVIEW1

René F. Ketting

| | |
|---|-----------|
| Abstract..... | 1 |
| Introduction: PTGS in Plants and Small RNAs..... | 1 |
| RNAi..... | 2 |
| Dicer | 2 |
| Argonaute | 4 |
| The First microRNAs and Links to RNAi..... | 4 |
| miRNAs: Ancient Mediators of Gene Regulation | 5 |
| Primary miRNA Processing by Drosha | 6 |
| Small RNA Selectivity of Argonaute Proteins | 7 |
| Target Recognition..... | 7 |
| Mechanisms of miRNA-Mediated Silencing..... | 8 |
| Regulating miRNAs | 10 |
| Conclusion | 10 |

2. REGULATION OF pri-miRNA PROCESSING THROUGH Smads.....15

Akiko Hata and Brandi N. Davis

| | |
|---|-----------|
| Abstract..... | 15 |
| Introduction: Basic TGFβ Signaling..... | 15 |
| miRNA Biogenesis..... | 17 |
| The First Processing Step by Drosha | 19 |
| R-Smads Regulate miRNA Maturation | 20 |
| Mechanism of Regulation of Specific pri-miRNAs by Smad | 22 |
| Transcriptional Regulation of miRNA Genes by Smads | 24 |
| Conclusion and Future Prospects..... | 24 |

3. STIMULATION OF pri-miR-18a PROCESSING BY hnRNP A128

Gracjan Michlewski, Sonia Guil and Javier F. Cáceres

| | |
|---|----|
| Abstract..... | 28 |
| Introduction..... | 28 |
| hnRNP A1 Binds to The pri-miR-18a Stem-Loop Structure | 29 |
| hnRNP A1 Promotes The Drosha-Mediated Processing of pri-miR-18a | 30 |
| Role of The Terminal Loops in miRNA Processing | 31 |
| Conclusion and Future Prospects..... | 33 |

4. KSRP PROMOTES THE MATURATION OF A GROUP OF miRNA PRECURSORS36

Michele Trabucchi, Paola Briata, Witold Filipowicz, Andres Ramos,
Roberto Gherzi and Michael G. Rosenfeld

| | |
|--|----|
| Abstract..... | 36 |
| Introduction..... | 36 |
| Co-Activators and Co-Repressors of miRNA Precursor Maturation | 37 |
| Impact of KSRP and Other Co-Activators and Co-Repressors of miRNA Precursor Maturation on Cell Proliferation, Differentiation and Cancer..... | 39 |
| Conclusion | 41 |

5. HORMONAL REPRESSION OF miRNA BIOSYNTHESIS THROUGH A NUCLEAR STEROID HORMONE RECEPTOR43

Sally Fujiyama-Nakamura, Kaoru Yamagata and Shigeaki Kato

| | |
|---|----|
| Abstract..... | 43 |
| Introduction..... | 43 |
| p68/p72 DEAD-Box RNA Helicases Serve as RNA-Binding Components in the Drosha Complex..... | 44 |
| Gene Regulation by Nuclear Estrogen Receptors..... | 46 |
| Estrogen-Induced mRNA Stability is Mediated through Horizontally Regulated miRNA Biosynthesis..... | 49 |
| Conclusion | 52 |

6. AUTOREGULATORY MECHANISMS CONTROLLING THE MICROPROCESSOR56

Robinson Triboulet and Richard I. Gregory

| | |
|--|----|
| Abstract..... | 56 |
| Introduction..... | 56 |
| Posttranscriptional Regulation of DGCR8 by the Microprocessor..... | 59 |
| Stabilization of Drosha Protein by DGCR8..... | 61 |
| Conclusion | 61 |

7. REGULATION OF pre-miRNA PROCESSING67

Nicolas J. Lehrbach and Eric A. Miska

| | |
|--|----|
| Abstract..... | 67 |
| Introduction..... | 67 |
| miRNAs and Developmental Timing in <i>C. elegans</i> | 68 |
| The Heterochronic Gene <i>lin-28</i> encodes a Regulator of <i>let-7</i> microRNA Processing | 69 |
| Lin28/LIN-28 Promotes Uridylation and Degradation of Pre- <i>let-7</i> | 71 |
| Heterochronic Gene Orthologues: Ancient Stem Cell Regulators? | 71 |
| Conclusion | 73 |

8. THE EFFECT OF RNA EDITING AND ADARs ON miRNA BIOGENESIS AND FUNCTION76

Bret S.E. Heale, Liam P. Keegan and Mary A. O'Connell

| | |
|---|----|
| Abstract..... | 76 |
| Introduction..... | 76 |
| Prevalence of Edited miRNAs..... | 78 |
| Effects of Editing of pri-miRNAs and pre-miRNAs on Biogenesis | 80 |
| The Effect of Editing on miRNA Function | 81 |
| ADARs as Competing dsRNA-Binding Proteins | 82 |
| Editing of Seed Target Sequences within 3'UTRs..... | 82 |
| Conclusion | 83 |

9. miRNAs NEED A TRIM: REGULATION OF miRNA ACTIVITY BY Trim-NHL PROTEINS85

F. Gregory Wulczyn, Elisa Cuevas, Eleonora Franzoni and Agnieszka Rybak

| | |
|---|----|
| Abstract..... | 85 |
| Introduction..... | 86 |
| The Trim-NHL Family of Developmental Regulators | 87 |
| The Trim Domain as E3 Ubiquitin Ligase | 89 |
| Functional Analysis of Individual Trim-NHL Family Members | 90 |
| Trim-NHL Proteins as Regulators of the miRNA Pathway | 95 |
| Conclusion | 99 |

10. PROPERTIES OF THE REGULATORY RNA-BINDING PROTEIN HuR AND ITS ROLE IN CONTROLLING miRNA REPRESSION.....106

Nicole-Claudia Meisner and Witold Filipowicz

| | |
|--|-----|
| Abstract..... | 106 |
| Introduction to HuR and ARE Elements..... | 106 |
| Regulation of the Regulator | 108 |
| Molecular Mechanisms of Posttranscriptional Control by HuR..... | 112 |
| Function of HuR in the Relief of miRNA-Mediated Repression | 114 |
| Synergism between HuR and <i>let-7</i> in Translational Repression of <i>c-Myc</i> mRNA..... | 117 |
| Conclusion | 118 |

| | |
|---|------------|
| 11. TURNOVER OF MATURE miRNAs AND siRNAs IN PLANTS AND ALGAE | 124 |
| Heriberto Cerutti and Fadia Ibrahim | |
| Abstract | 124 |
| Introduction | 125 |
| Small RNA Processing | 126 |
| Small RNA Modification by 2'-O-Methylation | 126 |
| Small RNA Loading and Activation of the RNA-Induced Silencing Complex..... | 128 |
| Mature Small RNA Degradation by Ribonucleases..... | 130 |
| Quality Control of Mature Small RNAs | 133 |
| Conclusion | 134 |
| | |
| 12. MicroRNases AND THE REGULATED DEGRADATION OF MATURE ANIMAL miRNAs..... | 140 |
| Helge Großhans and Saibal Chatterjee | |
| Abstract..... | 140 |
| Introduction | 140 |
| microRNA Biogenesis and Function..... | 141 |
| XRN-2, a Multifunctional Exoribonuclease | 143 |
| Degradation of <i>C. elegans</i> miRNAs by XRN-2..... | 144 |
| Is miRNA Turnover a Substrate-Specific Event? | 148 |
| A Function of XRN-2 in miRNA Turnover beyond <i>C. elegans</i>? | 148 |
| Half-Lives of miRNAs—Not all miRNAs are Equal..... | 149 |
| Target Availability Affects Release of miRNAs from AGO and their Subsequent Degradation..... | 151 |
| Conclusion | 152 |
| | |
| INDEX..... | 157 |

CHAPTER 1

microRNA BIOGENESIS AND FUNCTION

An Overview

René F. Ketting*

Abstract: During the last decade of the 20th century a totally novel way of gene regulation was revealed. Findings that at first glance appeared freak features of plants or *C. elegans* turned out to be mechanistically related and deeply conserved throughout evolution. This important insight was primed by the landmark discovery of RNA interference, or RNAi, in 1998. This work started an entire novel field of research, now usually referred to as RNA silencing. The common denominator of the phenomena grouped in this field are small RNA molecules, often derived from double stranded RNA precursors, that in association with proteins of the so-called Argonaute family, are capable of directing a variety of effector complexes to cognate RNA and/or DNA molecules. One of these processes is now widely known as microRNA-mediated gene silencing and I will provide a partially historical framework of the many steps that have led to our current understanding of microRNA biogenesis and function. This chapter is meant to provide a general overview of the various processes involved. For a comprehensive description of current models, I refer interested readers to the reviews and primary literature references provided in this chapter and to the further contents of this book.

INTRODUCTION: PTGS IN PLANTS AND SMALL RNAs

In the early 90s a number of papers were published that revealed an activity in Tobacco and Petunia plants that was triggered by repetitive transgenic DNA and that resulted in the silencing of that DNA and any other DNA bearing significant homology to the trigger (cosuppression).^{1,2} At least part of these phenomena acted downstream of transcription, through destabilization of mRNA and hence was named “Post-Transcriptional Gene Silencing” (PTGS). The molecular trigger of this phenomenon was not clear, although

*René F. Ketting—Hubrecht Institute-KNAW and University Medical Centre Utrecht, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands. Email: r.ketting@hubrecht.eu

it was speculated that “aberrant” RNA or double stranded RNA (dsRNA) were good candidates for priming PTGS. Although aberrant RNAs still play an important role in many models on RNA-mediated silencing events in plants, for example as templates on which dsRNA is synthesized, we now know that dsRNA is indeed in most cases the primary trigger. Furthermore, in 1999 a landmark paper from David Baulcombe and colleagues identified small RNA molecules as potential “specificity determinants” in PTGS.³ This hypothesis has turned out to be absolutely correct and the identification of this type of small RNA species helped to lay the basis for an outburst of research activity on RNA-based silencing processes in the years that followed.

RNAi

In 1998, double-stranded RNA (dsRNA) was first described as a very potent and specific agent for gene silencing in *C. elegans*. The term RNA interference was coined to refer to the described silencing effects, a term that is now usually abbreviated to RNAi.⁴ This ground-breaking work, published by Craig Mello, Andrew Fire and their colleagues, was awarded the Nobel Prize in 2006. Mello and Fire noted that RNAi targets exonic regions in RNA and leads to decreased RNA levels, consistent with a model in which RNAi leads to sequence specific mRNA destabilization, as had been found for cosuppression in plants. It was also noted that dsRNA could very well be a trigger in plant cosuppression, since inverted repeat sequences had been described as very potent triggers of PTGS. Soon after this paper, RNAi-like processes were identified in numerous other systems.⁵ Biochemical experiments in *Drosophila* started to reveal a mechanistic framework of RNAi,^{6,7} while genetics in *C. elegans* was revealing endogenous functions for RNAi and genes required for it.^{8,9} It appeared that RNAi could mechanistically be roughly divided into two steps: an initiation step and an effector step (Fig. 1).¹⁰ In the initiation step small RNAs are generated from the dsRNA trigger; in the effector step these small RNAs guide an Argonaute protein-containing complex named RNA-Induced Silencing Complex (RISC) to cognate mRNAs. The realization that small RNA molecules (then named siRNAs, for short interfering RNAs), like those described by Baulcombe in Tobacco plants undergoing PTGS, rather than long dsRNA molecules provided the sequence specificity of the whole process,^{7,11} enabled efficient RNAi also in mammalian cells.¹² This provided a highly efficient way to perform reverse genetic experiments in cell culture systems, a finding that has revolutionized research on mammalian cells.

DICER

Dicer, the enzyme that generates siRNAs from dsRNA, was identified in 2001.¹³ This enzyme contains two RNase III active sites, a so-called PAZ domain (named after three proteins in which this domain was first recognized: Piwi, Argonaute and Zwiille), a helicase domain and a dsRNA-binding domain. It binds to the ends of dsRNA substrates and introduces a staggered double-stranded break further along the dsRNA.¹⁴ The catalytic activity is very characteristic and always leaves a 3'-hydroxyl group, a 5'-phosphate group and a two base overhang at the 3' end. The length of the small RNA generated can vary, but usually is between 20 and 25 bases. Within one organism, different Dicer




Figure 1. Schematic comparison between RNAi and miRNA mechanisms. For a more detailed scheme of miRNA action see Figure 2. “RdRP activity” refers to RNA-dependent RNA polymerase activity that in plants and yeast can turn ssRNA into dsRNA that is subsequently cleaved by Dicer. Likely, this is a major source for the dsRNA trigger in PTGS. The scissors indicate passenger strand and target cleavage. The dashed lines crossing from RNAi to miRNA and vice versa indicate that the separation between these pathways is not absolute: side effects from siRNAs in RNAi experiments can be triggered through miRNA like activities and miRNAs are capable of inducing target cleavage if presented with a properly matching target RNA. The type of silencing induced is also strongly dependent on the sub-type of Argonaute protein involved.

genes can be present, each encoding a protein generating rather specific subsets of small RNA products.¹⁵ Mammals, however, only have one Dicer gene.